THE IMPACT OF TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION ON THE BELGIAN HEALTHCARE SYSTEM: RESULTS FROM A BUDGET IMPACT MODEL

REFERENCES

• Buchanan RW, Carpenter WT. Schizophrenia: introduction and overview. In: B.J. Sadock and V.A. Sadock, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Philadelphia, PA. Lippincott Williams &Wilkins. 2000:1096–1110.
   Google Scholar
• Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 1998; 24: 75–85.
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophre-nia. Economic and clinical issues. Pharmacoeconomics 2000; 18:106–124.
   PubMed Web of Science ®Google Scholar
• Rice D. The economic impact of schizophrenia. J Clin Psychiatry 1999; 60:4–6.
   PubMed Web of Science ®Google Scholar
• De Hert M, Thys E, Boydens J, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998; 24: 519–527.
   PubMed Web of Science ®Google Scholar
• Davies L, Drummond M. Economics and schizophrenia: the real cost. Br J Psy-chiatry 1994; 165: 18–21.
   Web of Science ®Google Scholar
• Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346–351.
   PubMed Web of Science ®Google Scholar
• Carpenter WT, Jr., Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990; 147:1138–1148.
   PubMed Web of Science ®Google Scholar
• Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 1991; 48: 333–339.
   PubMed Web of Science ®Google Scholar
• Andreasen N, Carpenter W, Kane J, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441–449.
   PubMed Web of Science ®Google Scholar
• Llorca PM. Partial compliance in schizophrenia and the impact on patient out-comes. Psychiatry Res 2008; 161: 235–247.
   PubMed Web of Science ®Google Scholar
• Weiden P, Zygmunt A. Medication noncompliance in schizophrenia. Part I. Assessment. J Pract Psychiatry Behav Health 1997; 3: 106–110.
   Google Scholar
• Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159:103–108.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psy-chiatry 2001; 62: 545–551.
   Web of Science ®Google Scholar
• Davis J, Metalon L, Watanabe M, Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741–773.
   PubMed Web of Science ®Google Scholar
• Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997; 68: 377–392.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Mulvihill T. latrogenic disorders associated with conventional vs. atypical antipsychotics. Ann Clin Psychiatry 2001; 13: 215–227.
   PubMedGoogle Scholar
• Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43:135–145.
   PubMed Web of Science ®Google Scholar
• Gerlach J. Oral versus depot administration of neuroleptics in relapse preven-tion. Acta Psychiatr Scand Suppl 1994; 382: 28–32.
   PubMedGoogle Scholar
• Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophre-nia. CNS Drugs 2004; 18: 113–132.
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperi-done: efficacy and safety of the first long-acting atypical antipsychotics. Am J Psych 2003; 160:1125–1132.
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12 month evaluation of the first long-acting 2nd generation antipsychotic. J Clin Psychiatry 2003; 64: 1250–1257.
   PubMed Web of Science ®Google Scholar
• Moller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121–130.
   PubMed Web of Science ®Google Scholar
• Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperi-done: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004; 19: 241–249.
   PubMed Web of Science ®Google Scholar
• van Os J, Bossie C, Lasser R. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004; 19: 229–232.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65: 1084–1089.
   PubMed Web of Science ®Google Scholar
• Gastpar M, Masiak M, Latif MA, et al. Sustained improvement of clinical out-come with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 2005; 19:32–38.
   PubMed Web of Science ®Google Scholar
• Marinis TD, Saleem PT, Glue P, et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007; 40:257–263.
   PubMed Web of Science ®Google Scholar
• Lasser R, Bossie C, Gharabawi G, Baldessarini R. Clinical improvement in 336 sta-ble chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005; 8:427–438.
   PubMed Web of Science ®Google Scholar
• Schmauss M, Sacchetti E, Kahn JP, Medori R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 2007; 22: 85–92.
   PubMed Web of Science ®Google Scholar
• Medori R, Wapenaar R, de Arce R, et al. Relapse prevention and effectiveness in schizophrenia with risperidone long-acting injectable (RLAI) versus quetiapine. Presented at: Annual Meeting of the American Psychiatric Association. 2008. Washington D.C., USA.
   Google Scholar
• Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schiz-ophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005; 19: 5–14.
   PubMed Web of Science ®Google Scholar
• Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008; 28: 210–213.
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Zhu Y, et al. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry 2004; 19: 898–905.
   PubMed Web of Science ®Google Scholar
• Singh D, O'Connor DW. Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia. Clin Intery Aging 2009; 4:351–355.
   Web of Science ®Google Scholar
• Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disor-der. J Affect Disord 2004; 83: 263–275.
   PubMed Web of Science ®Google Scholar
• Mohl A, Westlye K, Opjordsmoen S. et al. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 2005; 19: 22–31.
   PubMed Web of Science ®Google Scholar
• Ciliberto N, Bossie CA, Urioste R, Lasser RA. Lack of impact of race on the effi-cacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 2005; 20: 207–212.
   PubMed Web of Science ®Google Scholar
• Nasrallah H, Duchesne I, Mehnert A, Janagap C. Health-related quality of life with schizophrenia during treatment with long-acting risperidone injection. J Clin Psychiatry 2004; 65: 531–536.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. Per-ceived functioning, well-being and psychiatric symptoms in patients with sta-ble schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 2005; 187:131–136.
   PubMed Web of Science ®Google Scholar
• Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone--analysis of long-term efficacy. J Psychopharmacol 2005; 19: 15–21.
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005; 77: 215–227.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther 2008; 46: 14–22.
   PubMed Web of Science ®Google Scholar
• Rossi A, Bagala A, Del Curatolo V. et al. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2009; 24: 574–583.
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P. Koen L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008; 23: 325–331.
   PubMed Web of Science ®Google Scholar
• Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004; 13: 811–816.
   PubMed Web of Science ®Google Scholar
• Chue P. Devos E, Duchesne I, Leal A, Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. Int J Neu-ropsychopharmacol 2002; 5(Suppl 1): S1–5241.
   Google Scholar
• Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007; 116:36–46.
   PubMed Web of Science ®Google Scholar
• Taylor M, Currie A, Lloyd K, Price M, Peperell K. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharma-col 2008; 22:128–131.
   Web of Science ®Google Scholar
• Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007; 33: 1379–1387.
   PubMed Web of Science ®Google Scholar
• Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006; 114: 14–20.
   PubMed Web of Science ®Google Scholar
• Fuller M, Shermock K, Russo P. et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009; 12: 317–324.
   PubMedGoogle Scholar
• Taylor D, Cornelius V. Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up. J Psy-chopharmacol 2010; 24: 995–999.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Mertens C, Kusters J, et al. Long-acting risperidone in the treatment of schizophrenia: data from a 24-month Belgian electronic schizophrenia treat-ment adherence registry (e-STAR): an observational study. Acta Psychiatr Belg 2010; 2010: 34–46.
   Google Scholar
• De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005; 23 Suppl 1: 35–47.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPQR Task Force on good research prac-tices--budget impact analysis. Value Health 2007; 10: 336–347.
   PubMed Web of Science ®Google Scholar
• FOD Economie Statbel. 2008. Available at: http://www.statbel.fgov.be/figures/d21_nl.asp. Accessed: April 2011.
   Google Scholar
• Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
   PubMed Web of Science ®Google Scholar
• Fa lkai P. Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132–191.
   Web of Science ®Google Scholar
• National Institute for Clinical Excellence. The clinical effectiveness and cost effec-tiveness of newer atypical antipsychotic drugs for schizophrenia (TA43). 2002. Available from: http://www.nice.org.uk/guidancefindexjsp?action=bylD&o=11460. Accessed: April 2011.
   Google Scholar
• American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154: 1–63.
   Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open ran-domised clinical trial. Lancet 2008; 371: 1085–1097.
   PubMed Web of Science ®Google Scholar
• Rijksinstituut Voor Zielcte- en Invaliditeitsverzekering (RIZIV; National Institute for Health Insurance). 2008. Available from: http://www.riziv.fgov.be/. Accessed:
   Google Scholar
• Institit National d'Assurance Maladie Invalidité (INAMI; National Institute for Sickness and Invalidity Insurance). Prix de journée d'hospitalisation. 2008. Avail-able at: http://www.inami.fgov.be/caregr/hospitals/specific-information/prices-day/xls/prices2008.xls. Accessed: April 2011.
   Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antip-sychotics in Spain: results from the electronic Schizophrenia Treatment Adher-ence Registry (e-STAR). Eur Psychiatry 2009; 24: 287–296.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Martinez A, Buron JA, Alonso-Escolano D, Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008; 6:41–53.
   PubMedGoogle Scholar
• Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizo-phrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009; 25: 2197–2206.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treat-ment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010; 26: 501–509.
   PubMed Web of Science ®Google Scholar
• INAMI (Institit National d'Assurance Maladie Invalidité/ National Institute for Sickness and Invalidity Insurance). Prix de journée d'hospitalisation, January 2008; http://www.inami.fgov.be/caregr/hospitals/specific-information/prices-day/xls/prices2008.xls.
   Google Scholar
• Llorca PM, Miadi-Fargier H, Lançon C, et al. Cost-effectiveness analysis of schiz-ophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encephale 2005; 31: 235–246.
   PubMed Web of Science ®Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, Diamond RJ. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005; 23 Suppl 1: 75–89.
   PubMed Web of Science ®Google Scholar
• Chue PS, Heeg B, Buskens E, van Hout BA. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeco-nomics 2005; 23 Suppl 1: 62–74.
   Google Scholar
• Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risp-eridone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005; 23 Suppl 1: 49–61.
   PubMed Web of Science ®Google Scholar
• Chue P. Llorca P. Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005; 5: 266–274.
   Google Scholar
• Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psy-chopharmacol 2005; 20: 213–221.
   PubMed Web of Science ®Google Scholar
• Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic med-ications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001; 62: 855–859.
   PubMed Web of Science ®Google Scholar
• Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medica-tion for patients with schizophrenia. Psychol Med 2003; 33: 83–89.
   PubMed Web of Science ®Google Scholar
• Wistedt B. How does the psychiatric patient feel about depot treatment, com-pulsion or help. Nord J Psychiatry 1995; 49: 41–46.
   Web of Science ®Google Scholar
• Svedberg B, Backenroth-Ohsako G, Lutzen K. On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medica-tion. Int J Ment Health Nurs 2003; 12: 110–118.
   PubMed Web of Science ®Google Scholar
• Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300–307.
   PubMed Web of Science ®Google Scholar
• Keith S. Use of long-acting risperidone in psychiatric disorders: focus on effi-cacy, safety and cost-effectiveness. Expert Rev Neurother 2009; 9:9–31.
   PubMed Web of Science ®Google Scholar
• Barnes T, Curson D. Long term depot antipsychotics - a risk-benefit assessment. Drug Safety 1994; 10: 464–479.
   PubMed Web of Science ®Google Scholar
• Pope HG, Jr., Keck PE, Jr., McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143: 1227–1233.
   PubMed Web of Science ®Google Scholar
• Deng MZ, Chen GQ Phillips MR. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychia-try 1990; 147:1149–1155.
   PubMed Web of Science ®Google Scholar
• Marder SR. Depot neuroleptics: side effects and safety. J Clin Psychopharmacol 1986; 6: 245–295.
   Google Scholar
• Glazer WM. Depot fluphenazine: risk/benefit ratio. J Clin Psychiatry 1984; 45: 28–35.
   PubMed Web of Science ®Google Scholar
• Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426–433.
   PubMed Web of Science ®Google Scholar
• Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997; 95:464–468.
   PubMed Web of Science ®Google Scholar
• Marland GR, Sharkey V. Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature. J Adv Nurs 1999; 30: 1255–1262.
   PubMed Web of Science ®Google Scholar
• Amdur MA. Impractical features of long-acting risperidone. Psychiatr Sem 2004; 55: 1443; author reply 43–44.
   Google Scholar